Trial Profile
A Phase I/II Trial of Hsp 90 Inhibitor AUY-922 in Patients With Lung Adenocarcinoma With "Acquired Resistance" to EGFR Tyrosine Kinase Inhibitors.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Luminespib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 24 Oct 2018 Status changed from active, no longer recruiting to completed.
- 09 Jan 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
- 09 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.